Interim Report
Cimzia®, Vimpat® and Neupro® build momentum

- **Financial performance in-line with company expectations**
- **Continuing roll-out of major new products Cimzia®, Vimpat® and Neupro®**
- **Start of Phase I study for antibody fragment CDP7657**
- **Financial outlook 2010 confirmed**

Brussels (Belgium), April 29, 2010 – 07:00 (CEST) – regulated information – UCB announced today its interim report for the first quarter of 2010.

"In the first three months of 2010 more than 116 000 patients benefited from UCB's new medicines," said Roch Doliveux, CEO of UCB. "Our new products Cimzia®, Vimpat® and Neupro® are building momentum and laying the foundation for UCB's future growth. After the first three months we are also delighted to confirm that we are on track to deliver our guidance."

The new products Cimzia®, Vimpat® and Neupro® showed solid growth with multiple new launches proceeding as planned across various European countries. In addition, the company's anti-epileptic drug, Keppra® (*levetiracetam*), continued to grow in most European countries, due to continued increase in its use in monotherapy. The growth drivers largely offset the expected revenue decline in the first quarter 2010 compared to the same period in 2009 due to the effect of Keppra® U.S. patent expiry and the impact of the divestitures to GlaxoSmithKline (GSK) and Shire made at the end of March 2009. Underlying profitability (recurring EBITDA) and net profit performance were also in line with the company's expectation.

New product launches

The roll-out of Cimzia® (*certolizumab pegol*) in the U.S. and in Europe continues with now more than 11 300 patients treated with the drug worldwide. Cimzia® has established strong loyalty among specialist physicians and patients in the U.S. and Switzerland for the treatment of Crohn's Disease. Prescription data for Cimzia® in rheumatoid arthritis is promising in every one of the countries where it is available now: U.S., Denmark, Finland, Germany, Netherlands, Norway, Sweden and U.K. The number of prescriptions for Cimzia® in the treatment of Crohn's disease (CD) and rheumatoid arthritis (RA) in the U.S. is growing faster than competition with a 18.2%[1] and a 3.4%[2] share respectively of new prescriptions (NRx) in the subcutaneous anti-TNF market.

[1] IMS Xponent weekly prescriptions for CD in U.S., week ending 16 April 2010
[2] IMS National Prescription Audit (NPA) Weekly for RA in U.S., week ending 16 April 2010

UCB Corporate Communications - Allée de la Recherche, 60 - B-1070 Brussels (Belgium) www.ucb.com

The new anti-epileptic drug, Vimpat® *(lacosamide)* made a good start in the 17 markets where UCB has already launched with more than 50 000 patients benefiting from the drug. Available in Europe and in the U.S. as an add-on therapy for the treatment of partial-onset seizures, Vimpat® continues to gain market share. The successful launch in the U.S. epilepsy market is reflected by a strong prescription take-off: 2.1% NRx shares[3]. Additionally, Vimpat® is growing rapidly in Europe with treatment day shares (TDx) among new anti-epileptic drugs (AEDs) with 2.4%[4] in Germany, for example.

The launch roll-out of Neupro® (*rotigotine)* continues in Europe during the first quarter of 2010. Since the approval by the European Commission in June 2009 for UCB to again promote Neupro® for Parkinson's disease, and to launch the drug for restless legs syndrome, more than 54 700 patients are currently being treated with the drug in Europe. Neupro® is now available in Germany, Italy, Spain and the U.K. and in 15 other European markets for Parkinson's disease. Treatment day shares (TDx) in Parkinson's disease reached 15.1%[5] in Spain. Neupro® is now launched in Germany, the U.K., Ireland and Austria for restless legs syndrome. Launches in other European markets are following.

In the U.S., Food and Drug Administration (FDA) has provided end of last week a Complete Response Letter recommending the reformulation of Neupro® before making it available in the U.S. market for the treatment of Parkinson's disease and restless legs syndrome. FDA's response is to an NDA Supplement UCB submitted in June 2009, with a proposal for new refrigerated storage conditions to alleviate crystallisation on the patches. While FDA agreed that the proposed new refrigeration conditions significantly inhibit the degree of crystallisation on the patches, they have recommended that the definitive resolution of the crystallisation is to reformulate the drug product. This FDA decision does not impact product supply and availability in Europe and other countries. It also does not change previous assessments made by the European and other countries' authorities regarding the cold chain storage process. UCB has already been working on a room-temperature, stable improved formulation of Neupro® and has made significant progress in this area. Neupro® has made a meaningful difference for many people with Parkinson's disease and restless legs syndrome. UCB is committed to obtaining FDA approval so that people in the U.S. who live with these diseases can benefit from Neupro®.

New project for the development pipeline

In the area of immunology, a new compound was introduced to the Phase I programme: CDP7657, a humanised anti-CD40L antibody fragment which acts by preventing the interaction between CD40L on T cells with CD40 on antigen presenting cells. CDP7657 was developed with UCB's innovative technologies and is run in collaboration with Biogen Idec (NASDAQ: BIIB). The drug candidate is targeted at patients with systemic lupus erythematosus (SLE) and this Phase I study includes both healthy volunteers and patients with SLE.

3 IMS National Prescription Audit, February 2010- New AED epilepsy use
4 IMS retail Feb 2010, UCB calculations.
5 IMS retail Feb 2010, UCB calculations.

Outlook 2010 unchanged

Total revenue is expected to reach approximately EUR 3.0 billion in 2010. This reflects generic and mature products erosion as well as impacts of the divestitures made early 2009. These impacts should be partially offset by the growth of the newly launched products Cimzia®, Vimpat® and Neupro®.

In 2010, UCB's recurring EBITDA is expected to reach approximately EUR 700 million. Core EPS[6] 2010 is expected to reach approximately EUR 1.76 (based on 180 million non-diluted shares).

For further information

Antje Witte, Investor Relations UCB
T +32.2.559.9414, antje.witte@ucb.com

Richard Simpson, Investor Relations, UCB
T+32.2.559.9494, richard.simpson@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, michael.tuck-sherman@ucb.com

Nancy Nackaerts, External Communications, UCB
T +32.473.864.414 or +32.2.559.92.64, nancy.nackaerts@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9 000 people in over 40 countries, UCB produced revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).

Forward looking statement

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

[6] Core EPS (earnings per share) are calculated to reveal the inherent sustainable value of the net profit. For this calculation, per share net profit after minorities is adjusted for the after tax effects of non-recurring items (e.g. impairment and restructuring charges, extraordinary income, one-time financial or tax related expenses) and for the after tax impact of amortisation charges of intangible assets.